In a multicenter phase II study with Nilotinib, a novel phenylaminopyrimidine derivate with potent activity against KIT, KIT amplification alone was detected in 35.7% of melanoma and combined with KIT mutations in 4.8%. The gene discussed is KIT; the disease is melanoma.